Raltitrexed
- Generic Name
- Raltitrexed
- Brand Names
- Tomudex
- Drug Type
- Small Molecule
- Chemical Formula
- C21H22N4O6S
- CAS Number
- 112887-68-0
- Unique Ingredient Identifier
- FCB9EGG971
- Background
Raltitrexed (brand name Tomudex®) is a chemotherapy drug manufactured AstraZeneca Company, is an antimetabolite used in chemotherapy. It is an inhibitor of thymidylate synthase.
- Indication
For the treatment of malignant neoplasm of colon and rectum
- Associated Conditions
- Advanced Colorectal Cancer, Pleural Mesotheliomas
Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2017-02-14
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 100
- Registration Number
- NCT03053167
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shenyang, Liaoning, China
Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly
- Conditions
- Rectal Neoplasms Malignant
- Interventions
- First Posted Date
- 2016-12-14
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 68
- Registration Number
- NCT02992886
- Locations
- 🇨🇳
Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Beijing, China
Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2017-10-02
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 82
- Registration Number
- NCT02618356
- Locations
- 🇨🇳
Fudan University Cancer Hospital, ShangHai, Shanghai, China
Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer
- Conditions
- Head and Neck Squamous Cell Cancer
- Interventions
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2015-06-30
- Lead Sponsor
- Jiangsu Cancer Institute & Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT02485548
- Locations
- 🇨🇳
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients
- Conditions
- Colorectal Carcinoma
- Interventions
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT02376452
- Locations
- 🇨🇳
Fudan University Cancer Hospital, ShangHai, Shanghai, China
Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2014-02-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 140
- Registration Number
- NCT02072317
- Locations
- 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China
Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- First Posted Date
- 2013-10-09
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
- Target Recruit Count
- 320
- Registration Number
- NCT01959061
- Locations
- 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer
- First Posted Date
- 2013-04-19
- Last Posted Date
- 2013-04-19
- Lead Sponsor
- Hebei Tumor Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT01836120
- Locations
- 🇨🇳
Hebei Tumor Hospital, Shijiazhuang, Hebei, China
A Phase-II Study Of Raltitrexed/Oxaliplatin Plus Radiotherapy Versus Radiotherapy In Subjects With Inoperable Esophageal Cancer
- Conditions
- Inoperable Esophageal Cancer Stage I-III
- Interventions
- First Posted Date
- 2012-11-22
- Last Posted Date
- 2012-11-22
- Lead Sponsor
- The First People's Hospital of Lianyungang
- Target Recruit Count
- 108
- Registration Number
- NCT01732380
- Locations
- 🇨🇳
The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, China
Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer
- Conditions
- Rectal Cancer
- Interventions
- Radiation: Radiation therapy
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 62
- Registration Number
- NCT01481545
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.